Target intelligence / Profile preview

Microbial ribosomal protein (MRP)

Target
MRP
Molecular classification
Ribosomal protein, Ribonucleoprotein complex component, Translation factor
01

Overview

Microbial ribosomal proteins are essential structural and functional components of the bacterial ribosome, the complex molecular machine responsible for translating genetic information into proteins (Wilson, 2014, Cold Spring Harb Perspect Med). In bacteria, these proteins are organized into two subunits, the small 30S and the large 50S, which together form the functional 70S ribosome (Arenz & Wilson, 2016, Nature Reviews Microbiology). These proteins play critical roles in stabilizing ribosomal RNA (rRNA) and facilitating the various stages of translation, including initiation, elongation, and termination. Because bacterial ribosomes differ significantly in structure from eukaryotic 80S ribosomes, they serve as highly selective targets for a wide range of antimicrobial agents such as aminoglycosides, macrolides, and tetracyclines (StatPearls, 2023). Drugs targeting these proteins or their associated rRNA interfere with protein production, resulting in bacteriostatic or bactericidal effects. These targets are fundamental in treating infectious diseases, though their clinical utility is increasingly challenged by the emergence of resistance mechanisms, including target site modifications and enzymatic inactivation (PubMed, 2021).

Other names
Bacterial ribosomal proteinProkaryotic ribosomal proteinr-protein70S ribosomal protein30S ribosomal protein50S ribosomal protein
02

Mechanism of action

Inhibition of bacterial protein synthesis by binding to the 30S or 50S ribosomal subunits, leading to the disruption of mRNA decoding, inhibition of peptide bond formation, or prevention of ribosomal translocation.

03

Biological functions

Protein synthesisTranslationRibosome assemblyRNA binding
04

Disease associations

InfectionAntimicrobial resistance
05

Safety considerations

Mitochondrial toxicity due to structural similarity between bacterial and human mitochondrial ribosomes (PubMed, 2021)Ototoxicity and nephrotoxicity (specifically with aminoglycosides) (StatPearls, 2023)Disruption of the host commensal microbiomeSelection pressure leading to multi-drug resistant (MDR) strains
06

Interacting drugs

Gentamicin

16 more in the full profile.

07

Biomarkers

Minimum Inhibitory Concentration (MIC)Ribosomal protein mutations (e.g., rpsL, rplC, rplD)Ribosomal RNA (rRNA) methylation statusPresence of resistance genes (e.g., erm, tet, cfr)

Beyond the preview

Go deeper on Microbial ribosomal protein (MRP).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Microbial ribosomal protein (MRP).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call